Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib in advanced cholangiocarcinoma
NCT04919642Phase 2Completed
- Sponsor
- TransThera Biosciences
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tinengotinib in cholangiocarcinoma (CCA) (4 cohorts), sponsored by TransThera Biosciences. Primary endpoint: Objective Response Rate at 9 months. Started Dec 2021; status: completed.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04919642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919642.